Odyssey shakes hands on $500m-plus deal for Linden's ProPharma Group

Odyssey previously weighed buying ProPharma through existing portfolio company TrialCard, three sources said.

22 September 2020•3 mins read
Ares Capital, Alcami, pharmaceutical services, private equity, merger, M&A
LinkedInXEmail
LinkedInXEmail

Related articles